Analysis Verifies Adverse Effects of T-DX for HER2-Low BC.

Published Date: 16 May 2023

Trastuzumab deruxtecan is used to treat HER2-low metastatic breast cancer, and a safety analysis following a randomized phase 3 trial confirms that patients who take it frequently experience nausea and vomiting.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Mobile prostate cancer screening clinic can ID the disease in disadvantaged men

2.

Clinical trial is testing whether heavy lifting could combat cancer side effects

3.

NIH research cuts leave cancer patient facing hard choice

4.

Nonmelanoma skin cancer has been linked to occupational exposure to solar UVR.

5.

A video animation guide to assist young people who are fatigued from cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot